CD19 CAR T cell therapy BY19 for pediatric and adult patients with relapsed or refractory B cell neoplasms in Belarus: Phase 1 trial

Access to chimeric antigen receptor (CAR) T cell therapy remains limited in many developing countries. We conducted a single-arm, open-label, phase 1 trial (NCT05333302) at two Belarusian centers, evaluating an in-house manufactured CD19 CAR T cell product (BY19) in pediatric and adult patients with...

Cijeli opis

Bibliografski detalji

Glavni autori:	Mikalai Katsin, Dmitri Dormeshkin, Alexandr Migas, Olga Karas, Tatsiana Shman, Yuliya Serada, Yauheniya Khalankova, Hanna Klych, Dzmitry Lutskovich, Alena Lukoika, Alexander Meleshko
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2025-12-01
Serija:	Molecular Therapy: Oncology
Teme:	MT: Regular Issue CD19 CAR T cells decitabine B cell acute lymphoblastic leukemia B-ALL diffuse large B cell lymphoma
Online pristup:	http://www.sciencedirect.com/science/article/pii/S295032992500150X
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!